Long-term outcome in acquired aplastic anemia treated with an intensified dose schedule of horse antilymphocyte globulin in combination with androgens

Annals of Hematology

Volumn 85, Issue 10, 2006, Pages 711-716

  Leleu, Xavier ^a,b   Terriou, Louis ^a   Duhamel, Alain ^a   Moreau, Anne Sophie ^a   Andrieux, Joris ^a   Dupire, Sophie ^a   Coiteux, Valérie ^a   Berthon, Céline ^a   Micol, Jean Baptiste ^a   Guieze, Romain ^a   Facon, Thierry ^a   Bauters, Francis ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Androgens; Aplastic anemia; Horse antilymphocyte globulin; Late clonal complications

Indexed keywords

ANDROGEN; CYCLOSPORIN; LYMPHOCYTE ANTIBODY; LYMPHOGLOBULINE; METHYLPREDNISOLONE; NORETHANDROLONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG RESPONSE; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; KARYOTYPE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SECOND CANCER; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANDROGENS; ANEMIA, APLASTIC; ANIMALS; ANTILYMPHOCYTE SERUM; CHROMOSOME ABERRATIONS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HORSES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 33747382040     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-006-0152-y     Document Type: Article

References (21)

1. Killick SB, Marsh JC (2000) Aplastic anaemia: Management. Blood Rev 14:157-171
2. Frickhofen N, Rosenfeld SJ (2000) Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporine. Semin Hematol 37:56-68
3. Bacigalupo A, Broccia G, Corda G, Arcese W, Carotenuto M, Gallamini A, Locatelli F, Mori PG, Saracco P, Todeschini G et al (1995) Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): A pilot study of the EBMT SAA Working Party. Blood 85:1348-1353
4. Marsh JC, Gordon-Smith EC (1998) Treatment options in severe aplastic anaemia. Lancet 351:1830-1831
5. Ball SE (2000) The modern management of severe aplastic anaemia. Br J Haematol 110:41-53
6. Young NS, Maciejewski J (1997) The pathophysiology of acquired aplastic anemia. N Engl J Med 336:1365-1372
7. Socie G, Gluckman E (2000) Cure from severe aplastic anemia in vivo and late effects. Acta Haematol 103:49-54
8. Bacigalupo A, Chaple M, Hows J, Van Lint MT, McCann S, Milligan D, Chessells J, Goldstone AH, Ottolander J, van't Veer ET et al (1993) Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPred) with or without androgens: A randomized trial from the EBMT SAA working party. Br J Haematol 83:145-151
9. Paquette RL, Tebyani N, Frane M, Ireland P, Ho WG, Champlin RE, Nimer SD (1995) Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: Comparison with bone marrow transplantation. Blood 85:283-290
10. Bacigalupo A, Hows J, Gluckman E, Nissen C, Marsh J, Van Lint MT, Congiu M, De Planque MM, Ernst P, McCann S et al (1988) Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): A report of the EBMT SAA working party. Br J Haematol 70:177-182
11. Kaplan E, Meier P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
12. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170
13. Cox DR (1972) Regression models and life-tables. J R Stat Soc B 34:187
14. SPSS (1986) SPSS/PC+: Statistical package for social science, user's guide. SPSS, Chicago, IL
15. Kaltwasser JP, Dix U, Schalk KP, Vogt H (1988) Effect of androgens on the response to antithymocyte globulin in patients with aplastic anaemia. Eur J Haematol 40:111-118
16. Champlin RE, Ho WG, Feig SA, Winston DJ, Lenarsky C, Gale RP (1985) Do androgens enhance the response to antithymocyte globulin in patients with aplastic anemia? A prospective randomized trial. Blood 66:184-188
17. Schrezenmeier H, Marin P, Raghavachar A, McCann S, Hows J, Gluckman E, Nissen C, van't Veer-Korthof ET, Ljungman P, Hinterberger W et al (1993) Relapse of aplastic anaemia after immunosuppressive treatment: A report from the European Bone Marrow Transplantation Group SAA Working Party. Br J Haematol 85:371-377
18. Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS (2002) Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 99:3129-3135
19. Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A (2000) Late clonal diseases of treated aplastic anemia. Semin Hematol 37:91-101
20. Mikhailova N, Sessarego M, Fugazza G, Caimo A, De Filippi S, van Lint MT, Bregante S, Valeriani A, Mordini N, Lamparelli T, Gualandi F, Occhini D, Bacigalupo A (1996) Cytogenetic abnormalities in patients with severe aplastic anemia. Haematologica 81:418-422
21. Camitta B, O'Reilly RJ, Sensenbrenner L, Rappeport J, Champlin R, Doney K, August C, Hoffmann RG, Kirkpatrick D, Stuart R, Santos G, Parkman R, Gale RP, Storb R, Nathan D (1983) Antithoracic duct lymphocyte globulin therapy of severe aplastic anemia. Blood 62:883-888